Ultra Market Research | Viral Vectors and Plasmid DNA Manufacturing Market

Viral Vectors and Plasmid DNA Manufacturing Market

  • Report ID : 902

  • Category : Biotechnology,Global

  • No Of Pages : 100

  • Published on: December 2024

  • Status: Published

  • Format : Power Point PDF Excel Word

Key Question Answer

check-box

Global Market Outlook

check-box

In-depth analysis of global and regional trends

check-box

Analyze and identify the major players in the market, their market share, key developments, etc.

check-box

To understand the capability of the major players based on products offered, financials, and strategies.

check-box

Identify disrupting products, companies, and trends.

check-box

To identify opportunities in the market.

check-box

Analyze the regional penetration of players, products, and services in the market.

check-box

Comparison of major players financial performance.

check-box

Evaluate strategies adopted by major players.

check-box

Recommendations

Viral Vectors and Plasmid DNA Manufacturing Market

Introduction

Viral Vectors & Plasmid DNA Manufacturing Market plays an integral role in gene therapy, vaccine development, and cell-based therapies. It uses viral vectors and plasmid DNA to deliver genetic material into cells for the treatment of various genetic disorders, cancers, and infectious diseases. Viral vectors such as adenoviruses, lentiviruses, and adeno-associated viruses are more commonly used for transferring genes into patient cells, and plasmid DNA has a critical role in the production of gene vaccines and therapeutic proteins.
The market is highly growing due to the increase in genetic disorders, a rise in demand for cell and gene therapies, and developments in viral vector production technologies. The Viral Vectors & Plasmid DNA Manufacturing Market was valued at around USD 1.5 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15% from 2024 to 2030. North America is holding the largest market share at present, thanks to its robust healthcare infrastructure and significant investments in biotech research. This market's growth trajectory is on the way to growing application in therapeutic areas and expanding regulatory support.

 

Market Segmentation

Type of Product
•    Viral Vectors
o    Adenovirus
o    Lentivirus
o    Adeno-associated virus (AAV)
o    Others
•    Plasmid DNA
o    Linear Plasmid DNA
o    Circular Plasmid DNA
o    Others


Application
•    Gene Therapy
o    Inherited Disorders
o    Cancer Therapy
o    Others
•    Vaccine Development
o    DNA Vaccines
o    Viral Vector Vaccines
o    Others
•    Cell-based Therapy
o    CAR-T Therapy
o    Stem Cell Therapy
o    Others


End User
•    Pharmaceutical & Biotechnology Companies
o    Large Enterprises
o    Small and Medium Enterprises (SMEs)
•    Contract Research Organizations (CROs)
o    Vaccine Manufacturing
o    Clinical Trials Support
•    Academic Research Institutes
o    Research & Development (R&D)
o    Clinical Research


Production Scale
•    Small-scale Production
o    Pilot Production
o    Clinical-Grade Production
•    Large-scale Production
o    Commercial Production
o    Bulk Manufacturing

 

List of Market Players
•    Lonza Group (Switzerland)
•    WuXi AppTec (China)
•    Merck Group (Germany)
•    Cell and Gene Therapy Catapult (UK)
•    Biolife Solutions, Inc. (USA)
•    AGC Biologics (USA)
•    Viralgen Vector Core (Spain)
•    Oxford Biomedica (UK)
•    Cevipof Technologies (France)
•    Kite Pharma (USA)
•    Pharming Group (Netherlands)
•    Tocagen (USA)
•    Novartis Gene Therapies (USA)
•    Takara Bio (Japan)
•    Genscript Biotech Corporation (China)

 

Drivers

The key factors driving the growth of Viral Vectors & Plasmid DNA Manufacturing Market are an increase in gene therapies, mainly for genetic disorders, treatment of cancer, and rare diseases, where the demand is increasing for high-quality viral vectors and plasmid DNA. Increasing pipelines of gene-based vaccines and cell-based therapies also support the market's expansion.
Bioprocessing technologies are also continuously improving, and efficiencies in the vector production processes have made it cheaper and scalable, hence vital to meet the needs of large-scale manufacturing of gene therapies. Moreover, governments and healthcare authorities worldwide are making significant investments in gene therapy infrastructure and providing regulatory support, thereby promoting the development of the sector. Market dynamics are also driven by rising investments in precision medicine research and healthcare spending. This shows a bright future for the viral vectors and plasmid DNA manufacturing market.

 

Restraints

Despite having strong growth prospects, the Viral Vectors & Plasmid DNA Manufacturing Market has several challenges to overcome. High production costs in the manufacturing of viral vectors and plasmids are one of the significant hurdles for small to medium-sized biotech firms. The production of viral vectors is quite complex and includes problems like scalability and quality control. Regulatory hurdles, along with lengthy approval processes for new gene therapies, also delay market entry and product commercialization.
In addition, the potential for immune reactions in patients who are treated with viral vector-based therapies is a safety issue that may slow adoption. The lack of standardization in manufacturing processes and the scarcity of skilled labor in the field of gene therapy production also contribute to market constraints. These issues will have to be addressed to ensure long-term sustainable growth.

 

Opportunities 

The Viral Vectors & Plasmid DNA Manufacturing Market presents numerous attractive opportunities to the stakeholders. The first key opportunity is that of increased genetic diseases and cancers; viral vector-based therapies may be a major area of hope. The second area of the development of DNA vaccines and mRNA-based therapies creates new openings for the viral vector and plasmid DNA market.
Expansion of gene editing technologies such as CRISPR is another factor that will fuel growth. Moreover, with the rising interest in personalized medicine, there is a growing demand for scalable, cost-efficient manufacturing of viral vectors and plasmid DNA. Strategic collaborations between pharmaceutical companies, biotechs, and academic institutions will further accelerate innovation. These factors present numerous opportunities for businesses involved in this market to capitalize on.

 

Trends

The Viral Vectors & Plasmid DNA Manufacturing Market is undergoing several transformative trends. The most prominent trend is the automation of the manufacturing process, which enhances efficiency and reduces the likelihood of human error. This is increasingly adopted for scaling up production of gene therapies without increasing costs disproportionately.
Another important trend is next-generation viral vectors, for example, optimized AAVs and lentiviruses, which show higher transfection efficiency and lower immunogenicity. Modular production systems are also advancing, which allows easier scalable production in a flexible, cost-effective manner.
Cell-free expression systems are becoming popular in the production of plasmid DNA. They increase yield and minimize the risk of contamination. The frequency of ongoing collaborations and partnerships between leading pharmaceutical companies and contract manufacturing organizations (CMOs) is on the rise, thereby providing more opportunities for suppliers of viral vector and plasmid DNA. Finally, regulatory support for gene therapies is increasing and is a significant trend driving the growth of the market.

 

Approved Products and Pipeline

•    Zolgensma (AAV vector-based therapy, approved for spinal muscular atrophy)
•    Kymriah (CAR-T cell therapy, uses lentiviral vector)
•    Luxturna (AAV-based gene therapy for retinal dystrophy)
•    Vaxzevria (AstraZeneca's COVID-19 vaccine, uses adenovirus vector)
Pipeline Products:
•    Strimvelis (Gene therapy for ADA-SCID)
•    Yescarta (CAR-T therapy using lentivirus vector)
•    Valoctocogene roxaparvovec (Gene therapy for hemophilia A)

 

Key Target Audience

•    Pharmaceutical & Biotechnology Companies
•    Healthcare Providers & Hospitals
•    Academic & Research Institutes
•    Contract Manufacturing Organizations (CMOs)
•    Regulatory Authorities
•    Investors and Market Analysts
•    Gene Therapy Researchers
•    Vaccine Developers
•    Clinical Research Organizations (CROs)
•    Biopharmaceutical Manufacturing Units

 

Frequently Added Questions (FAQs)

 

As of 2023, the market size is valued at approximately USD 1.5 billion and is expected to grow at a CAGR of 15% from 2024 to 2030.
The main applications include gene therapy, vaccine development, and cell-based therapies.
North America holds the largest market share, followed by Europe and Asia-Pacific.
The increasing prevalence of genetic diseases, advancements in gene therapies, and the growing demand for personalized medicine are key drivers.
High production costs, regulatory challenges, and concerns regarding patient safety are some of the challenges hindering market growth.

Choose License Type

  • $3999

  • $5550

  • $6999

Our Reports Look Like This

Ultra Market Research

HAVE A QUESTION

will help you find what you are looking for:


Related Reports

Recent Reports

Subscribe to Newsletter

Provide your email to get email notification when we publish new reports.

whatsapp